|
|
Volumn 101, Issue 24, 2009, Pages 1664-1667
|
|
Companies waver in efforts to target transforming growth factor beta in cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
MONOCLONAL ANTIBODY;
PROTEIN KINASE INHIBITOR;
TRANSFORMING GROWTH FACTOR BETA;
ANIMAL;
CELL PROLIFERATION;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG EFFECT;
DRUG INDUSTRY;
GENETICS;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
METABOLISM;
METHODOLOGY;
MOUSE;
MULTIMODALITY CANCER THERAPY;
NEOPLASM;
NOTE;
PATHOLOGY;
PERSONALIZED MEDICINE;
TRANSGENIC MOUSE;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CELL PROLIFERATION;
CLINICAL TRIALS AS TOPIC;
COMBINED MODALITY THERAPY;
DRUG INDUSTRY;
HUMANS;
IMMUNOTHERAPY;
INDIVIDUALIZED MEDICINE;
MICE;
MICE, TRANSGENIC;
NEOPLASMS;
OLIGONUCLEOTIDES, ANTISENSE;
PROTEIN KINASE INHIBITORS;
TRANSFORMING GROWTH FACTOR BETA;
|
|
EID: 73449089494
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp462 Document Type: Note |
|
Times cited : (33)
|
|
References (0)
|
